Ekso Bionics (OTC:EKSO) said it raised nearly $23 million in a secondary offering for its Ekso GT exoskeleton, but must file for 510(k) clearance from the FDA after the watchdog agency raised the risk classification on powered exoskeletons.
Ekso said it sold warrants at $1 per share to raise $22.7 million it plans to use to boost sales & marketing, expand clinical testing and win reimbursement for the Ekso GT device, which is designed to increase mobility for wheelchair-bound patients.
Help employers find you! Check out all the jobs and post your resume.
